Search

S-8510

S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

Dodecyldimethylamine N-oxide

N-Ethylmaleimide

A sulfhydryl reagent that is widely used in experimental biochemical studies. [PubChem]

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal … Calpain is the primary protease that degrades skeletal muscle.

XL999

XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.

Itopride

Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

Guanabenz

Guanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.

Altropane

Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

Dichlorvos

Dichlorvos is found in urban waterways and its toxicity may impact humans, leading to poisoning, neurotoxicity, and cancer. … The compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns.

MBO7133

However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step … in the activation pathway of the drug.